share_log

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations Is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations Is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago

在2024年美國心臟協會(AHA)在芝加哥舉行的四個Lexicon支持的演示之一,展示了Sotagliflozin在廣泛範圍的心力衰竭患者群體中的好處的事後分析。
GlobeNewswire ·  11/14 21:00

Study results add to the growing body of evidence differentiating sotagliflozin within SGLT inhibitor class

研究結果增加了區分sotagliflozin在SGLt抑制劑類別中的證據。

THE WOODLANDS, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from four studies of sotagliflozin will be delivered during the American Heart Association's (AHA) Sessions 2024 being held November 16-18 at McCormick Place Convention Center in Chicago, Illinois.

美國德克薩斯州伍德蘭,2024年11月14日(全球新聞稿)-- 萊斯康製藥公司(納斯達克:LXRX)今日宣佈,將在2024年11月16日至18日於伊利諾伊州芝加哥的麥考密克會展中心舉行的美國心臟協會(AHA)會議上發佈四項關於sotagliflozin的研究數據。

One of those studies, a secondary analysis of data from the Phase 3 SCORED clinical trial, examined the association of heart failure stage with cardiovascular disease and kidney events. Researchers in the study observed that sotagliflozin had similar relative benefits for all endpoints, irrespective of heart failure stage, with a corresponding increase in absolute benefits at earlier stages.

其中一項研究是對3期SCORED臨床試驗數據的二次分析,研究了心力衰竭階段與心血管疾病和腎臟事件的關聯。研究人員觀察到sotagliflozin對所有結局具有相似的相對獲益,無論心力衰竭階段如何,在早期階段有明顯的絕對獲益增加。

Details of the four presentations are as follows:

四個展示的詳細信息如下:

  • "Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Transporters 1 and 2, Elicits Cardioprotective Effects Through Attenuation of Platelet Activation and Thrombosis," -- a poster presentation, Saturday, November 16, 4:17-4:27p.m. CT, Poster# 4134384, South Level 1, Area S104B, presented by Livia Stanger, Ph.D. candidate, University of Michigan, Ann Arbor, Michigan
  • 「Sotagliflozin,鈉-葡萄糖轉運蛋白1和2的雙重抑制劑,通過減輕血小板活化和血栓形成引發心臟保護效果,」-- 一場海報演示,2024年11月16日星期六,4:17-4:27 p.m. Ct,海報編號# 4134384,南層1,區域S1040億,由密歇根大學安阿伯的博士生Livia Stanger呈現。
  • "Effect of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, on Systolic Blood Pressure in Patients with Type 2 Diabetes," -- a poster presentation, Sunday, November 17. 11:30a.m.-12:30p.m., Poster# Su3019, Posters Zone 3, presented by M. Belinda Hardin, PharmD, US Medical Affairs, Lexicon Pharmaceuticals, Inc.
  • "Sotagliflozin對2型糖尿病患者收縮壓的影響" -- 一場海報展示,時間爲11月17日,星期日,上午11:30至12:30,海報號Su3019,海報區3,由m. Belinda Hardin,藥學博士,美國醫療事務,萊斯康製藥公司呈現。
  • "Association of the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients with Diabetes and Kidney Disease: A Secondary Analysis of the SCORED Trial," -- a moderated poster presentation, Sunday, November 17, 3:15-3:20p.m CT, Poster# MDP1133, Posters Zone 4, presented by Ayodele Odutayo, Ph.D., M.D., University of Toronto, Ontario
  • "2022 AHA/ACC/HFSA心力衰竭分期與糖尿病及腎病患者心血管和腎臟結果的關係:SCORED試驗的二次分析" -- 一場有主持的海報展示,時間爲11月17日,星期日,下午3:15-3:20,海報號MDP1133,海報區4,由Ayodele Odutayo,博士,萬.D.,多倫多大學,安大略省呈現。
  • "Sotagliflozin Reduces Contractile Work In Human Living Myocardial Slices," -- a poster presentation, Sunday, November 17, 3:15-4:15p.m. CT, Poster# Su1070, Poster Zone 1, South Level 3, Science & Technology Hall, presented by Rebecca Taichman, M.D. candidate, University of Pennsylvania, Philadelphia, Pennsylvania
  • "Sotagliflozin減少人類活體心肌切片的收縮工作" -- 一場海報展示,時間爲11月17日,星期日,下午3:15-4:15,海報號Su1070,海報區1,南層3,科學與科技大廳,由Rebecca Taichman,萬.D.候選人,賓夕法尼亞大學,費城,賓夕法尼亞州呈現。

"The post-hoc studies that will be presented at AHA reinforce our belief that sotagliflozin is differentiated within the SGLT inhibitor drug class. These studies help build a broad-based, scientific rationale supporting the dual mechanism of action of sotagliflozin," said Craig Granowitz, M.D., Ph.D., Lexicon's senior vice president and chief medical officer.

"在AHA上將要呈現的事後研究增強了我們對sotagliflozin在SGLT抑制劑藥物類別中有差異性的信念。這些研究有助於建立支持sotagliflozin雙重作用機制的廣泛科學依據," Lexicon的高級副總裁兼首席醫療官Craig Granowitz,萬.D.,博士說。

About Sotagliflozin
Discovered using Lexicon's unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients.

關於索他格列奈
sotagliflozin的發現是利用萊斯康製藥獨特的基因科學方法,它是一種口服抑制劑,能夠抑制兩種負責葡萄糖調節的蛋白質,稱爲鈉-葡萄糖共轉運蛋白2和1 (SGLT2和SGLT1)。SGLT2負責腎臟對葡萄糖和鈉的重吸收,而SGLT1則負責胃腸道對葡萄糖和鈉的吸收。sotagliflozin在大約2萬名患者中進行了多種病患群的研究,涉及心力衰竭、糖尿病和慢性腎病,以及臨床研究.

About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through the Genome5000 program, Lexicon's unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has commercially launched one of these medicines, INPEFA (sotagliflozin) in the United States, and has a pipeline of other promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit .

萊斯康製藥公司是一家以開創能夠改變患者生命爲使命的生物製藥公司。通過Genome5000計劃,萊斯康的科學家研究了將近5000個基因的作用和功能,並確定了100多個具有重大治療潛力的蛋白靶點,用精確的靶向這些蛋白質,萊斯康正在探索和開發治療疾病的創新藥物。在神經病理性疼痛、糖尿病和代謝以及其他治療領域中,萊斯康已經在美國上市了一種INPEFA(硫糖苷酸鈉)。萊斯康還有其他有前途的藥物開發項目,正在進行發現和臨床前和臨床開發。欲了解更多信息,請訪問
Lexicon是一家生物製藥公司,其使命是開創能夠改變患者生命的藥物。通過Genome5000計劃,Lexicon的獨特基因組目標發現平台,Lexicon科學家研究了近5000個基因的作用和功能,並確定了在多種疾病中具有顯著治療潛力的100多種蛋白質靶點。通過精確的靶向這些蛋白,Lexicon正在開創發現和開發治療疾病的創新藥物,以安全有效地治療疾病。Lexicon已在美國商業化推出了其中的一種藥物INPEFA(Sotagliflozin),並在具有神經病性疼痛、糖尿病和代謝以及其他適應症方面開發了其他有前途的藥物候選物。請訪問以上網址,獲取更多信息。

Safe Harbor Statement

Safe Harbor聲明

This press release contains "forward-looking statements," including statements relating to Lexicon's financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin and its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon's growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon's ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

本新聞稿包含「前瞻性聲明」,包括與萊斯康製藥的財務狀況及其業務的長期展望相關的聲明,包括其獲批產品的商業化及sotagliflozin和其他藥物候選的臨床開發、監管申請和潛在的治療及商業潛力。此外,本新聞稿還包含與萊斯康製藥的增長和未來運營結果、產品的發現、開發和商業化、戰略聯盟和知識產權相關的前瞻性聲明,以及其他非歷史性事實或信息。所有前瞻性聲明均基於管理層當前的假設和預期,並涉及風險、不確定性和其他重要因素,特別包括萊斯康製藥滿足資本需求的能力、成功商業化其獲批產品的能力、成功進行臨床前和臨床開發的能力,以及在預期時間內獲得其他藥物候選所需的監管批准,達到其運營目標,爲其發現申請專利保護,以及建立戰略聯盟的能力,以及與製造、知識產權和其獲批產品和其他藥物候選的治療或商業價值相關的其他因素。這些風險、不確定性和其他因素中的任何一個都可能導致萊斯康製藥的實際結果與任何由此類前瞻性聲明所表達或暗示的未來結果有顯著不同。識別此類重要因素的信息包含在萊斯康製藥截至2023年12月31日的年度報告10-K表格中的「風險因素」中,該報告已向證券交易委員會提交。萊斯康製藥沒有義務更新或修訂任何此類前瞻性聲明,無論是由於新信息、未來事件還是其他原因。

For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

投資者和媒體查詢:
Lisa DeFrancesco
萊斯康製藥公司
lexinvest@lexpharma.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論